A practical reference on reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-20 and is reviewed periodically as new material appears.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Finally, Marshall and coworkers found that P-selectin:PSGL-1 bonds exhibited increasing bond lifetime as step loads were applied between 0 and ~10 pN for monomeric interaction but 1 and ~20 pN for dimeric interaction, exhibiting catch bond behavior; after reaching maximum values, which were ~0.6 and 1.2 seconds for monomeric and dimeric interaction, respectively, the bond lifetime fell rapidly at higher loads, displaying slip bond behavior ("catch-slip" bonds). These data were collected using an atomic force microscope and a flow chamber, and have subsequently been duplicated using a biomembrane force probe. These finding prompted the discoveries of other important catch bonds in the 2000s, including those between L-selectin and PSGL-1 or endoglycan, FimH and mannose, myosin and actin, platelet glycoprotein Ib and von Willebrand factor, and integrin alpha 5 beta 1 and fibronectin. Emphasizing their importance and general acceptance, in the three years following their discovery there were at least 24 articles published on catch bonds. More catch bonds were discovered in the 2010s, including E-selectin with carbohydrate ligands, G-actin with G-actin or F-actin, cadherin-catenin complex with actin, vinculin with F-actin, microtubule with kinetochore particle, integrin alpha L beta 2 and intercellular adhesion molecule 1 (ICAM-1), integrin alpha 4 beta 1 with vascular adhesion molecule 1, integrin alpha M beta 2 with ICAM-1, integrin alpha V beta 3 with fibronectin, and integrin alpha IIb beta 3 with fibronectin or fibrinogen.
Meanwhile, workers in the platelet, extracellular matrix, and cell surface fields were also working on multi-subunit receptors. The platelet receptor for fibrinogen contained two glycoprotein subunits termed IIb and IIIa. A monoclonal antibody to a cell surface receptor that blocked cell adhesion to laminin and fibronectin reacted with three distinct subunits in the same molecular weight range as αLβ, αMβ, αXβ, and IIb/IIIa. Proteins with high molecular weight, sharing a common subunit, were identified on lymphocytes and non-hematopoietic cells. After the discovery that an RGD motif in fibronectin is sufficient for recognition by its receptor and common to other extracellular proteins, the fibronectin and vitronectin receptors were isolated and their sequences determined and platelet protein IIb/IIIa was also shown to recognize RGD. Sequences of these receptors showed that their alpha subunit sequences were homologous to one another and to those earlier reported for LFA-1 (αLβ) and Mac-1 (αMβ). A large number of other papers appeared in 1986-1987 reporting further sequences and relationships among these receptors, including from the Springer lab on the β-subunit shared by LFA-1 (αLβ), Mac-1 (αMβ), and αXβ. Richard Hynes chaired the 1987 Gordon Research Conference on Fibronectin. Hynes had worked on fibronectin, and in 1986 his group isolated a cDNA encoding a subunit recognized by an antibody to the laminin and fibronectin receptors, which he named integrin.
P. infula is widely distributed throughout boreal, montane and coastal forests in North America. The North American range extends north to Canada and south to Mexico. It has also been reported from South America, Europe, and Asia. The fungus can be found growing singly to scattered in or near coniferous woodland in autumn, often on rotten wood. It is also commonly found on packed ground, such as beside country roads, or in campgrounds. Associated conifers include Picea glauca, P. mariana, P. sitchensis, Pinus contorta, P. banksiana, P. monticola, Abies balsamea, A. grandis, Pseudotsuga menziesii, Tsuga heterophylla, Larix occidentalis, Thuja plicata, as well as the deciduous tree species Populus balsamifera, P. tremuloides, Acer macrophyllum, Alnus species, and Betula papyrifera.
=== Halides === Actinium trifluoride can be produced either in solution or in solid reaction. The former reaction is carried out at room temperature, by adding hydrofluoric acid to a solution containing actinium ions. In the latter method, actinium metal is treated with hydrogen fluoride vapors at 700 °C (1,292 °F) in an all-platinum setup. Treating actinium trifluoride with ammonium hydroxide at 900–1,000 °C (1,650–1,830 °F) yields oxyfluoride AcOF. Whereas lanthanum oxyfluoride can be easily obtained by burning lanthanum trifluoride in air at 800 °C (1,470 °F) for an hour, similar treatment of actinium trifluoride yields no AcOF and only results in melting of the initial product.
Rosiglitazone (Avandia): the European Medicines Agency recommended in September 2010 that it be suspended from the EU market due to elevated cardiovascular risks. Pioglitazone (Actos): remains on the market but has also been associated with increased cardiovascular risks. Troglitazone (Rezulin): used in 1990s, withdrawn due to hepatitis and liver damage risk. Multiple retrospective studies have resulted in a concern about rosiglitazone's safety, although it is established that the group, as a whole, has beneficial effects on diabetes. The greatest concern is an increase in the number of severe cardiac events in patients taking it. The ADOPT study showed that initial therapy with drugs of this type may prevent the progression of disease, as did the DREAM trial. The American Association of Clinical Endocrinologists (AACE), which provides clinical practice guidelines for management of diabetes, retains thiazolidinediones as recommended first, second, or third line agents for type 2 diabetes mellitus, as of their 2019 executive summary, over sulfonylureas and α-glucosidase inhibitors. However, they are less preferred than GLP-1 agonists or SGLT2 inhibitors, especially in patients with cardiovascular disease (which liraglutide, empagliflozin, and canagliflozin are all FDA approved to treat). Concerns about the safety of rosiglitazone arose when a retrospective meta-analysis was published in the New England Journal of Medicine.
Sources: en.wikipedia.org
As of 2024, the United Nations reports Ghana has a population of 34,581,288. As of 2018, around 29% of the population is under the age of 15, while persons aged 15–64 make up 57.8% of the population. The 2010 census reported that the largest ethnic groups are the Akan (47.3%), the Mole-Dagbani (18.5%), the Ewe (13.9%), the Ga-Dangme (7.4%), the Gurma (5.7%) and the Guan (3.7%). As of 2024, the United Nations reports the median age of Ghanaian citizens is 21 years old. Ghana contributes 0.42% to the total world population. With legal immigration of skilled workers who possess Ghana Cards, there is an increasing population of Chinese, Malaysian, Indian, Middle Eastern, American and European nationals and their descendants born in Ghana. In 2010, the Ghana Immigration Service reported economic migrants and undocumented immigrants inhabiting Ghana: 14.6% (or 3.1 million) of Ghana's 2010 population (mostly Nigerians, Burkinabe citizens, Togolese citizens, and Malian citizens). In 1969, under the "Ghana Aliens Compliance Order" enacted by then Prime Minister Kofi Abrefa Busia, the Border Guard Unit deported more than 3,000,000 aliens and undocumented immigrants in three months as they made up 20% of the population at the time. In 2013, there was a mass deportation of undocumented miners, more than 4,000 of whom were Chinese nationals.
=== Nutrition === The assessment of a client's nutritional status looks at their normal patterns of daily nutrition. Eating only portions of meals or having imbalanced nutrition can indicate a high risk in this category.
https://doi.org/10.1007/978-94-007-1060-3 Zhou, T., Li, N., Jin, Y., Zeng, Q., Prabowo, W., Liu, Y., Tian, C., Bao, L., Liu, S., Yuan, Z., Fu, Q., Gao, S., Gao, D., Dunham, R., Shubin, N. H., & Liu, Z. (2018). Chemokine C-C motif ligand 33 is a key regulator of teleost fish barbel development. Proceedings of the National Academy of Sciences, 115(22), E5018–E5027. https://doi.org/10.1073/pnas.1718603115
While transcription of prokaryotic protein-coding genes creates messenger RNA (mRNA) that is ready for translation into protein, transcription of eukaryotic genes leaves a primary transcript of RNA (pre-RNA), which first has to undergo a series of modifications to become a mature RNA. Types and steps involved in the maturation processes vary between coding and non-coding preRNAs; i.e. even though preRNA molecules for both mRNA and tRNA undergo splicing, the steps and machinery involved are different. The processing of non-coding RNA is described below (non-coding RNA maturation). The processing of pre-mRNA include 5′ capping, which is set of enzymatic reactions that add 7-methylguanosine (m7G) to the 5′ end of pre-mRNA and thus protect the RNA from degradation by exonucleases. The m7G cap is then bound by cap binding complex heterodimer (CBP20/CBP80), which aids in mRNA export to cytoplasm and also protect the RNA from decapping. Another modification is 3′ cleavage and polyadenylation. They occur if polyadenylation signal sequence (5′- AAUAAA-3′) is present in pre-mRNA, which is usually between protein-coding sequence and terminator. The pre-mRNA is first cleaved and then a series of ~200 adenines (A) are added to form poly(A) tail, which protects the RNA from degradation. The poly(A) tail is bound by multiple poly(A)-binding proteins (PABPs) necessary for mRNA export and translation re-initiation. In the inverse process of deadenylation, poly(A) tails are shortened by the CCR4-Not 3′-5′ exonuclease, which often leads to full transcript decay.
Sources: en.wikipedia.org
== Total synthesis == There is no reported total synthesis of chloroeremomycin, although there are several total syntheses of vancomycin. The structures of vancomycin and chloroeremomycin are very similar, differing only in the glycosylation sites. Vancomycin is glycosylated at aa4 with a (2-beta1)-Glc-vancosamine disaccharide. As mentioned above, chloroeremomycin is glycosylated at aa4 with a (2-beta1)-Glc-epivancosamine disaccharide and at aa6 with a beta1-epivancosamine saccharide.
=== Phosphotungstic acid === Phosphotungstic acid is a common negative stain for viruses, nerves, polysaccharides, and other biological tissue materials. It is mostly used in a .5-2% ph form making it neutral and is paired with water to make an aqueous solution. Phosphotungstic acid is filled with electron dense matter that stains the background surrounding the specimen dark and the specimen itself light. This process is not the normal positive technique for staining where the specimen is dark and the background remains light.
=== Endocrine === Dexamethasone is the treatment for the very rare disorder of glucocorticoid resistance. In adrenal insufficiency and Addison's disease, dexamethasone is prescribed when the patient does not respond well to prednisone or methylprednisolone. It can be used in congenital adrenal hyperplasia in older adolescents and adults to suppress adrenocorticotropic hormone (ACTH) production. It is typically given at night.
Securities and Exchange Commission prosecutor and Republican candidate for New York's 1st congressional district Robert Karem (2000), assistant secretary of defense for international security affairs and former acting under secretary of defense for policy David Segal (2001), member of the Rhode Island House of Representatives Robby Mook (2002), political campaign strategist and campaign manager for Virginia governor Terry McAuliffe, former executive director of Democratic Congressional Campaign Committee; campaign manager for Hillary Clinton presidential campaign, 2016 Sam Arora (2003), member of the Maryland House of Delegates 2011–2015 Cyrus Habib (2003), lieutenant governor of Washington, first and only Iranian American elected to a state office in the U.S. Adam Jentleson (2003), former deputy chief of staff to Harry Reid and columnist of GQ Nikil Saval (2005), former editor of N+1, member of the Pennsylvania State Senate Josie Raymond (2007), member of the Kentucky House of Representatives from the 31st district Ruthzee Louijeune (2008), president of the Boston City Council Sara Jacobs (2011), member of the United States House of Representatives for California's 53rd congressional district, granddaughter of Qualcomm founder Irwin M.
=== Kidney transplant === SIUT is performing deceased organ donation since two decades as one person loses his fight to live every 3 minutes due to end stage organ failure in the country. First renal transplant was performed at SIUT Chablani Medical Center, Sukkur on Sunday 28 April 2019.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.